ore g o n dre pro g ra m
play

Ore g o n DRE Pro g ra m Se rg e a nt E va n Se the r Ore g o n - PowerPoint PPT Presentation

Ore g o n DRE Pro g ra m Se rg e a nt E va n Se the r Ore g o n Sta te Po lic e T o pic s fo r Disc ussio n Ore g o n Drug Re c o g nitio n E xpe rt (DRE ) Pro g ra m Wha t a re we do ing a b o ut DUI I -Drug s? Q & A


  1. Ore g o n DRE Pro g ra m Se rg e a nt E va n Se the r Ore g o n Sta te Po lic e

  2. T o pic s fo r Disc ussio n  Ore g o n Drug Re c o g nitio n E xpe rt (DRE ) Pro g ra m  Wha t a re we do ing a b o ut DUI I -Drug s?  Q & A

  3. Ab o ut me  12 Ye a rs a s a po lic e o ffic e r  8 ye a rs a s a DRE  5 ye a rs a s a DRE I nstruc to r  3 ye a rs a s a n E MT

  4. Ore g o n DRE Pro g ra m Ove rvie w & Pro g ra m Sta ts

  5. Ore g o n DRE Pro g ra m  I nte rna tio na l pro g ra m initia te d in 1987, o ve rse e n b y NHT SA a nd I ACP.  Ore g o n’ s pro g ra m initia te d in 1995.  Curre ntly 220 DRE s in 74 diffe re nt a g e nc ie s a c ro ss the sta te , pre do mina ntly in Va lle y a nd Me tro a re a .  T his re pre se nts a ppro xima te ly 4% o f a ll la w e nfo rc e me nt o ffic e rs in the Sta te o f Ore g o n.

  6. Ore g o n DRE Pro g ra m  Pro g ra m ma na g e d b y the Ore g o n Sta te Po lic e – Pa tro l Se rvic e s Divisio n  F unde d b y ODOT g ra nts (no t inc luding sa la ry)  T ra ining : $230,000  Ove rtime : $125,000  Blo o d T e sting : $60,000

  7. Wha t is a Drug Re c o g nitio n E xpe rt?  Ce rtifie d la w e nfo rc e me nt o ffic e r.  E xpe rie nc e in DUI I / Drug e nfo rc e me nt a nd re c o mme nda tio ns fro m DRE s a nd pro se c uto rs.  72 ho urs o f c la ssro o m tra ining .  T a ug ht b y DRE I nstruc to rs, physic ia ns a nd E MT s.  40 ho urs o f fie ld c e rtific a tio n tra ining .  Supe rvise d e va lua tio ns a nd writte n re po rts.  Co mpre he nsive fina l kno wle dg e e xa mina tio n.  Co ntinuing e duc a tio n re q uire d.  Re -c e rtific a tio n pro c e ss e ve ry two ye a rs.

  8. Wha t is the DRE Pro to c o l?  12 Ste p Syste ma tic & Sta nda rdize d E va lua tio n  E va lua te s sub je c t’ s me dic a l, me nta l a nd physic a l c o nditio n.  Opinio n o f the E va lua to r (De c isio n Pro c e ss)  I s the sub je c t impa ire d?  I f so , is it a me dic a l impa irme nt o r drug impa irme nt?  I f a drug impa irme nt, wha t c a te g o ry/ c a te g o rie s o f drug s a re c a using the impa irme nt?

  9. T o o ls the DRE use s  BP Cuff  Ste tho sc o pe  Ora l the rmo me te r  Pupilo me te r  I nc a nde sc e nt Pe nlig ht  UV lig ht  Glo ve s

  10. De fining the te rm, “drug ”… Any substanc e that, whe n take n into the human body, c an impair the ability of the pe r son to ope r ate a ve hic le safe ly. Drug E va lua tio n & Cla ssific a tio n Pro g ra m

  11. De fining the te rm, “drug ”… Any substanc e that alte r s pe r c e ption or be havior , r e duc ing that individual’s ability to func tion in an ac ade mic e nvir onme nt. Drug I mpa irme nt T ra ining fo r E duc a tio na l Pro fe ssio na ls

  12. I ng e stio n / Ab so rptio n E xc re tio n Distrib utio n Me ta b o lism

  13. Why a re the re se ve n c a te g o rie s?  E a c h c a te g o ry c o nsists o f drug s tha t c a n impa ir a pe rso n’ s me nta l a nd physic a l a b ility.  T he c a te g o rie s diffe r in the wa y the drug s a ffe c t the b o dy.  T he c a te g o rie s diffe r in o b se rva b le sig ns a nd sympto ms o f impa irme nt.

  14. Dura tio n o f Drug E ffe c ts Dura tio n va rie s de pe nding o n:  Me tho d o f I ng e stio n  Do sa g e  Ag e  We ig ht  T o le ra nc e  I nte ra c tio ns with o the r drug s  Psyc ho a c tive me ta b o lite s vs. ina c tive me ta b o lite s

  15. Se ve n Drug Ca te g o rie s Ce ntra l Ne rvo us Syste m (CNS) De pre ssa nts Ce ntra l Ne rvo us Syste m (CNS) Stimula nts Ha lluc ino g e ns Dissoc iative Ane sthe tic s Na rc o tic Ana lg e sic s I nha la nts Ca nna b is

  16. Ore g o n DRE Pro g ra m Sta tistic s  1509 drug e va lua tio ns  813 (54%) we re in 2015 “po lydrug ”  760 – Ca nna b is  _ No t I mpa ire d  436 – CNS  _ Me dic a l De pre ssa nts  _ Alc o ho l o nly  476 – CNS Stimula nts  368 – Na rc o tic Ana lg e sic s  7 – Ha lluc ino g e ns  7 – Disso c ia te Ane sthe tic s  5 – I nha la nts

  17. Ho w ma ny Drug DUI I s a re the re in Ore g o n?  Are DRE e va lua tio ns a n a c c ura te me tric fo r sta te wide DUI I -Drug a rre sts?  2015: 3,510 sub je c ts b le w .00% - .07% o n a n I nto xilyze r 8000 b re a th te st instrume nt.  Ho w did we miss 57% o f the se po te ntia l c a ndida te s?

  18. Ho w did we miss 2001 pe o ple ? !  An unkno wn numb e r o f the se we re impa ire d b y o nly a lc o ho l a nd the inve stig a tio n sto ppe d the re .  So me sub je c ts re fuse d to pa rtic ipa te in a DRE e va lua tio n.  So me o ffic e rs did no t re c o g nize the sig ns o f drug impa irme nt.  No DRE s we re a va ila b le to pe rfo rm the e va lua tio n.

  19. Ho w ma ny Drug DUI I s a re the re in Ore g o n?  T he re is no wa y to a c c ura te ly tra c k drug DUI I s in Ore g o n.  Da ta : who c o lle c ts it, ho w is it c o de d, e tc .  I mplie d Co nse nt L a w do e s no t a ddre ss c o lle c tio n o f b lo o d/ urine if the sub je c t b lo ws o ve r .08%.  DUI I s a re g e ne ra lly no t tra c ke d b y sub sta nc e .

  20. Wha t do e s the DRE Pro g ra m do ?  T ra ining  DRE Sc ho o l  Adva nc e d Ro a dside I mpa ire d Driving E nfo rc e me nt (ARI DE )  Drug I mpa irme nt T ra ining fo r E duc a tio na l Pro fe ssio na ls (DI T E P)  Pre se nta tio ns to L e g isla ture , g o ve rnme nt g ro ups, pub lic g ro ups, stude nts, la w e nfo rc e me nt, pro se c uto rs, e tc .

  21. Wha t do e s the DRE Pro g ra m do ?  E nfo rc e me nt  DRE E va lua tio ns  DUI I e nfo rc e me nt  F uture : T ruc ke r Che c ks  F uture : Hig h Visib ility E nfo rc e me nt

  22. Wha t do e s the DRE Pro g ra m do ?  Da ta Co lle c tio n  DRE e va lua tio ns  Pre va le nc e o f drug c a te g o rie s  Re c re a tio na l vs OMMP c a nna b is use rs  Ca nna b is pro duc t type  Blo o d te sting fo r drug s

  23. DRE Blo o d T e sting Gra nt  Ne w for F F Y 2015- 2016 $60,000  169 b lo o d sa mple s te ste d fo r 141 inc ide nts.  T ra c king a va rie ty o f a spe c ts.  I nc ide nt type s  Drug pre va le nc e  T HC le ve ls  Blo o d sa mple c o lle c tio n de la ys  DRE e va lua tio ns a nd c o nfirma tio n %  Re ne we d for F F Y 2016- 2017 $120,000

  24. Q & A

Recommend


More recommend